Bicara Therapeutics Q4 Earnings Call Highlights

4 days ago 4

MarketBeat

Mon, March 30, 2026 astatine 9:11 AM CDT 8 min read

Bicara Therapeutics logo

Breakthrough Therapy Designation was granted for ficerafusp alfa positive pembrolizumab successful first-line metastatic/unresectable HPV‑negative HNSCC, and the programme has precocious into the Phase III FORTIFY‑HN01 survey with 1,500 mg selected arsenic the optimal biologic dose and an interim investigation expected mid‑2027; the proceedings is double‑blinded and absorption volition not beryllium unblinded.
Phase 1b information successful ~90 patients showed the 1,500 mg weekly cohort delivered a median duration of effect of 21.7 months and median wide endurance of 21.3 months, with tumor shrinkage crossed doses and deeper responses astatine higher exposure, supporting a loading signifier followed by every‑three‑week maintenance.
Bicara completed an oversubscribed nationalist offering that raised $161.8 million nett and entered 2026 with $414.8 million successful currency and equivalents, enabling accrued concern successful the pivotal programme and pre‑launch activities portion maintaining runway guidance into the first fractional of 2029.
Interested successful Bicara Therapeutics Inc.? Here are 5 stocks we similar better.

Bicara Therapeutics (NASDAQ:BCAX) utilized its inaugural quarterly net telephone to item caller regulatory momentum, updated objective information for its pb programme ficerafusp alfa, and a strengthened equilibrium expanse pursuing an oversubscribed nationalist offering.

Chief Executive Officer Claire Mazumdar described Bicara arsenic a clinical-stage biotech focused connected bifunctional antibodies for targeted tumor modulation, with its pb plus ficerafusp alfa (“ficera”) designed to harvester EGFR targeting with a TGF-beta ligand trap. Mazumdar said the attack is intended to localize to tumors portion modulating the tumor microenvironment to trim fibrosis and immunosuppression and to code TGF-beta-driven absorption mechanisms.

→ Quiet BNY and Northern Trust Reward Patient Investors

Mazumdar outlined respective developments since October 2025, including:

Breakthrough Therapy Designation from the FDA for ficerafusp alfa successful operation with pembrolizumab for first-line attraction of metastatic oregon unresectable HPV-negative recurrent caput and cervix squamous compartment carcinoma (HNSCC).
Presentation of further Phase 1b datasets crossed “clinically progressive doses,” which she said supported consistency successful wide effect rates and helped de-risk the wide effect complaint endpoint planned for an interim analysis.
Selection of 1,500 mg arsenic the optimal biologic dose and progression into the Phase III information of the pivotal FORTIFY-HN01 study, with an interim investigation expected “in the mediate of adjacent year,” according to Mazumdar.
A program to prosecute a loading and every-three-week attraction dosing strategy, which Mazumdar characterized arsenic a commercialized determination informed by updated clinical, translational, and pharmacokinetic data.
Completion of an oversubscribed nationalist offering to enactment accelerated concern successful aboriginal commercialized and aesculapian infrastructure.